| Carmen Leigh Vance, FNP-C | |
|
551 Lone Pine Blvd, The Dalles, OR 97058-9403 | |
| (541) 506-6920 | |
| Not Available |
| Full Name | Carmen Leigh Vance |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 551 Lone Pine Blvd, The Dalles, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144745860 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 201706123NP-PP (Oregon) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 201706123NP-PP (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Hood River Memorial Hospital | Hood river, OR | Hospital |
| Mid-columbia Medical Center | The dalles, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Family Medicine - Llc | 2961564703 | 8 |
News Archive
Despite adequate numbers of maternal health workers showing up to work, new research published on October 6th reveals it was the patients who stayed away at their own peril for fear of catching the disease.
Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.
Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.
In his Thursday appearance at a suburban Maryland community college, President Barack Obama dismissed as "crazy" the arguments being advanced by the overhaul's opponents and accused some GOP lawmakers of attempting "blackmail" to stop its implementation.
Workers in the social care sector are experiencing a number of difficulties with the interview process, according to a survey carried out by specialist recruiter Randstad Care.
› Verified 1 days ago
| Entity Name | Mid-columbia Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053409599 PECOS PAC ID: 3779487251 Enrollment ID: O20031209000244 |
News Archive
Despite adequate numbers of maternal health workers showing up to work, new research published on October 6th reveals it was the patients who stayed away at their own peril for fear of catching the disease.
Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.
Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.
In his Thursday appearance at a suburban Maryland community college, President Barack Obama dismissed as "crazy" the arguments being advanced by the overhaul's opponents and accused some GOP lawmakers of attempting "blackmail" to stop its implementation.
Workers in the social care sector are experiencing a number of difficulties with the interview process, according to a survey carried out by specialist recruiter Randstad Care.
› Verified 1 days ago
| Entity Name | Summit Family Medicine - Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811157902 PECOS PAC ID: 2961564703 Enrollment ID: O20090102000441 |
News Archive
Despite adequate numbers of maternal health workers showing up to work, new research published on October 6th reveals it was the patients who stayed away at their own peril for fear of catching the disease.
Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.
Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.
In his Thursday appearance at a suburban Maryland community college, President Barack Obama dismissed as "crazy" the arguments being advanced by the overhaul's opponents and accused some GOP lawmakers of attempting "blackmail" to stop its implementation.
Workers in the social care sector are experiencing a number of difficulties with the interview process, according to a survey carried out by specialist recruiter Randstad Care.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Carmen Leigh Vance, FNP-C 4295 Se Mason Hill Dr, Milwaukie, OR 97222-5097 Ph: (208) 412-8326 | Carmen Leigh Vance, FNP-C 551 Lone Pine Blvd, The Dalles, OR 97058-9403 Ph: (541) 506-6920 |
News Archive
Despite adequate numbers of maternal health workers showing up to work, new research published on October 6th reveals it was the patients who stayed away at their own peril for fear of catching the disease.
Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.
Incyte Corporation (Nasdaq: INCY) announced today that it has entered into a clinical trial collaboration agreement with Merck, through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer (NSCLC), and other advanced or metastatic cancers.
In his Thursday appearance at a suburban Maryland community college, President Barack Obama dismissed as "crazy" the arguments being advanced by the overhaul's opponents and accused some GOP lawmakers of attempting "blackmail" to stop its implementation.
Workers in the social care sector are experiencing a number of difficulties with the interview process, according to a survey carried out by specialist recruiter Randstad Care.
› Verified 1 days ago